The Food and Drug Administration authorized Novavax's single-strain vaccine, which targets omicron subvariant XBB.1.5, for emergency use in people ages 12 and up. The Centers for Disease Control and ...
Zacks Investment Research on MSN
Novavax (NVAX) falls more steeply than broader market: What investors need to know
In the latest close session, Novavax (NVAX) was down 4.18% at $8.95. This change lagged the S&P 500's daily loss of 1.74%. Elsewhere, the Dow saw a downswing of 1.01%, while the tech-heavy Nasdaq ...
The Biden administration announced Monday that it would purchase 3.2 million doses of the Novavax COVID-19 vaccine. It will be offered at no cost to states and federal partners. “We remain committed ...
Novavax swings to profit in Q4 CEO remains optimistic despite U.S. regulatory uncertainties Shares surge over 22% after strong results Feb 26 (Reuters) - Novavax (NVAX.O), opens new tab raised its ...
GAITHERSBURG, Md., May 12, 2023 /PRNewswire/ -- Novavax, Inc. (NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Singapore Health ...
What recent performance says about Novavax Novavax (NVAX) has been moving on the radar again, with shares showing a mix of shorter term pressure and stronger recent momentum that may have some ...
A federal judge blocked parts of HHS's vaccine policy changes, siding with medical groups against Robert F. Kennedy Jr.'s ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min It’s the second time the firm ...
Novavax Inc. said this week that its COVID-19 vaccine would not receive regulatory clearance in the U.S. or the U.K. until at least July, while a shortage of materials has delayed its production ...
IOWA CITY — News this week that Americans now have a fourth COVID-19 vaccine option — one closer to more traditional vaccines used to combat flu, for example — came about thanks, in part, to ...
Zacks Investment Research on MSN
Novavax (NVAX) stock moves -1.23%: What you should know
Novavax (NVAX) closed at $9.62 in the latest trading session, marking a -1.23% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 1.51% for the day. Meanwhile, the Dow ...
Novavax reported fourth-quarter earnings of 11 cents, a shift from a loss of 51 cents a year ago. evenue for the fourth quarter was $147 million, a 67% year-over-year increase. Novavax on Thursday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results